CT011
Hepatocellular Carcinoma
Key Facts
About CARsgen Therapeutics
CARsgen Therapeutics is a clinical-stage biopharma with a mission to develop and commercialize innovative cell therapies for cancer, aiming to make cancer curable. The company has established itself as a notable player in the challenging field of solid tumor CAR-T therapy, with its lead asset CT041 (targeting Claudin18.2) achieving key regulatory designations in both China and the U.S. Its strategy leverages a fully integrated platform spanning discovery to manufacturing, with a dual geographic footprint in Houston, USA, and Shanghai, China, to drive global development.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Namodenoson (CF102) | Can Fite Biopharma | Phase IIb/III |
| GC-101 | Genocury Biotech | Preclinical |
| DCR-MYC | Dicerna Pharmaceuticals | Preclinical |
| RYZ801 | RayzeBio | Preclinical |
| BRVT101 | Biorevert | Preclinical |
| BRVT121 | Biorevert | Phase I |
| BRVT151 | Biorevert | Phase I |
| HCC Diagnostic Test | Senseera | Clinical POC |
| RG6139 (RO7247669) | Chugai Pharmaceutical | Phase III |
| ALN-BCAT | Alnylam Pharmaceuticals | Phase 1 |
| HCC Program | Arcellx | Discovery |
| TTFields | Novocure | Pilot |